Armistice Capital Master Fund Purchases 564,000 Shares of Vaxart Inc (NASDAQ:VXRT) Stock

Vaxart Inc (NASDAQ:VXRT) major shareholder Armistice Capital Master Fund bought 564,000 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were acquired at an average price of $0.36 per share, with a total value of $203,040.00. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Armistice Capital Master Fund also recently made the following trade(s):

  • On Thursday, October 3rd, Armistice Capital Master Fund bought 436,000 shares of Vaxart stock. The shares were acquired at an average price of $0.35 per share, with a total value of $152,600.00.
  • On Monday, September 30th, Armistice Capital Master Fund bought 7,333,333 shares of Vaxart stock. The shares were acquired at an average price of $0.29 per share, with a total value of $2,126,666.57.

Shares of VXRT stock traded up $0.02 on Wednesday, hitting $0.38. The stock had a trading volume of 1,320 shares, compared to its average volume of 590,373. The company has a quick ratio of 2.29, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The business has a 50 day moving average price of $0.57 and a 200 day moving average price of $0.79. The company has a market cap of $5.71 million, a PE ratio of -0.14 and a beta of 0.57. Vaxart Inc has a one year low of $0.25 and a one year high of $5.00.

Vaxart (NASDAQ:VXRT) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.11. The firm had revenue of $0.09 million during the quarter, compared to the consensus estimate of $1.10 million. Vaxart had a negative return on equity of 131.05% and a negative net margin of 244.38%. Equities research analysts expect that Vaxart Inc will post -1.45 EPS for the current year.

VXRT has been the subject of several research analyst reports. HC Wainwright set a $2.00 target price on Vaxart and gave the stock a “buy” rating in a research report on Wednesday, August 21st. Zacks Investment Research upgraded Vaxart from a “hold” rating to a “buy” rating and set a $0.75 target price for the company in a research report on Friday, August 30th. ValuEngine downgraded Vaxart from a “buy” rating to a “hold” rating in a report on Monday, September 30th. Finally, Brookline Capital Management began coverage on Vaxart in a report on Thursday, August 15th. They issued a “buy” rating and a $6.00 price objective for the company.

An institutional investor recently raised its position in Vaxart stock. Vanguard Group Inc. lifted its position in Vaxart Inc (NASDAQ:VXRT) by 65.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 89,209 shares of the biotechnology company’s stock after acquiring an additional 35,283 shares during the quarter. Vanguard Group Inc. owned 0.57% of Vaxart worth $60,000 as of its most recent SEC filing. Institutional investors and hedge funds own 12.51% of the company’s stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus.

Featured Story: How does new data get added to a blockchain?

Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit